Physiotherapy Assessment Based on the ICF Model in The Lesch-Nyhan Syndrome: Case Report
Condition(s):Lesch-Nyhan SyndromeLast Updated:September 21, 2022Recruiting
Hide Studies Not Open or Pending
Condition(s):Lesch-Nyhan SyndromeLast Updated:September 21, 2022Recruiting
Condition(s):Lesch-Nyhan SyndromeLast Updated:June 24, 2005Completed
Condition(s):Behavioral Manifestations of Lesch-Nyhan DiseaseLast Updated:August 2, 2019Withdrawn
Condition(s):Lesch-Nyhan DiseaseLast Updated:April 18, 2013Completed
Condition(s):Lesch-Nyhan Disease; Self-injurious BehaviorLast Updated:October 8, 2015Terminated
Condition(s):AMPD3, OMIM*102772, AMP Deaminase Deficiency; AK1, OMIM *103000, Adenylate Kinase Deficiency; AMPD1, OMIM *102770, Myopathy Due to Myoadenylate Deaminase Deficiency; TPMT, OMIM *187680, Thoipurines, Poor Metabolism of; IMPDH1, OMIM *146690, Retinitis Pigmentosa Type 10, Leber Congenital Amauriosis Type 11; APRT, OMIM *102600, Adenine Phosphoribosyltransferase Deficiency; HPRT1, OMIM *308000 Lesch-Nyhan Disease; XDH, OMIM *607633, Xanthinuria Type 1; SLC2A9, OMIM *606142 Hypouricemia; SLC22A12, OMIM *607096 Hypouricemia; PRPS1 Def, OMIM *311850, Arts Syndrome; Charcot-Marie-Tooth Disease; PRPS1 SA, OMIM *311850 Gout, PRPS-related Phosphoribosylpyrophosphate Synthetase Superactivity; AMPD2, OMIM *102771, Spastic Paraplegia 63; Pontocerebellar Hypoplasia; ITPA, OMIM *147520, Inosine Triphosphatase Deficiency; Developmental and Epileptic Encephalopathy 35; ADSL, OMIM *608222, Adenylosuccinate Lyase Deficiency; PNP, OMIM *164050, Nucleoside Phosphorylase Deficiency; ADA2, OMIM *607575,Sneddon Syndrome; VAIHS; CAD, *1140120, Developmental and Epileptic Encephalopathy; UPB1, OMIM *606673, Beta-ureidopropionase Deficiency; DPYS, OMIM *613326, Dihydropyrimidinase Deficiency; DPYD, OMIM *274270, Dihydropyrimidine Dehydrogenase Deficiency; DHODH, OMIM *126064, Miller Syndrome (Postaxial Acrofacial Dysostosis); UMPS, OMIM *613891, Orotic Aciduria; NT5C3A<TAB>, OMIM *606224, Anemia, Hemolytic, Due to UMPH1 Deficiency; UNG, OMIM *191525, Hyper-IgM Syndrome 5; AICDA, OMIM *605257, Immunodeficiency With Hyper-IgM, Type 2; HIGM2; Purine-Pyrimidine Metabolism; Metabolic DiseaseLast Updated:February 9, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.